In the spring of this year, I had the opportunity to attend the 2nd International Comprehensive Cancer Care Conference in Rhodes, Greece. I left the meeting impressed with the cooperative nature of this international endeavor in palliative care. To follow is a summary of the important clinical areas that were discussed at this meeting.
Bone pain
Osteoclast activation is the primary mechanism in the development of bone metastases. Therefore, the osteoclast is the obvious therapeutic target. Bisphosphonates, such as intravenous pamidronate, not only suppress osteclast function but also enhance normal bone density and provide pain relief in about half of the patients treated. As presented by Dr. David Brooks of the University of Sheffield in the United Kingdom, new and more potent bisphosphonates are currently being developed and tested, including the following:
• alendronate (eight times as potent as pamidronate),
• risedronate (80 times as potent as pamidronate),
• ibandronate (200 times as potent as pamidronate), and
• zolendronate (850 times as potent as pamidronate).
However, these newer bisphosphonates-in comparison with the existing pamidronate-may provide only convenience, such as the route of administration. Pamidronate is also effective in reducing the number of pathologic fractures in patients with multiple myeloma and metastatic breast cancer. The use of bisphosphonates in preventing bone metastases remains controversial, in part due to the high costs.
Another approach to the management of metastatic bone disease is the use of radiation therapy. In one-fourth of patients, complete pain relief occurs at one month, with a median duration of pain relief of three months. Radiation therapy administered one time (single fraction) is just as effective as when given multiple times (multiple fractions). Of interest, the radioisotopes produce the same pain relief as radiation therapy.
Opioid rotation
The concept of rotating or switching from one opioid to another to achieve better pain relief with less bothersome side effects was introduced several years ago. Some studies suggest that switching from morphine to hydromorphone can enhance pain relief with a diminution in certain side effects, notably impaired mental status. Also, in a controlled study, transdermal fentanyl caused less constipation, drowsiness, and nausea than sustained release morphine did. Dr. Henry McQuay of Churchill Hospital, United Kingdom, even mentioned a strategy of opioid route rotation-that is, changing the route of administration of the same opioid rather than changing the drug. Unfortunately, his review of the literature failed to find sufficient scientific evidence to support this concept.
Clearly if the patient is having intolerable side effects due to morphine, changing to another opioid is necessary. In these situations, Dr. Robert Twycross International palliative care 1998
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Editorial Robert E. Enck, MD, Editor-in-Chief, Medical Director, St. Joseph Cancer Center, Reading, Pennsylvania. of Oxford University, United Kingdom, recommends using hydromorphone and oxycodone for cognitive failure, hallucinations or myoclonus, and methadone for opioid-induced hyperexcitability. Finally, the emerging importance of the NMDA (N-methyl-D-aspartate) receptor was stressed. The NMDA receptors play a role in the sensitization of central neurons following an injury. Methadone has activity at the NMDA receptor and may partially explain pain relief with methadone in patients who no longer respond to morphine or hydromorphone. More research is ongoing in this critical receptor area.
Adjuvant analgesics
Little difference exists in side effects between the antidepressants and the anticonvulsants, according to an evidence-based review of the literature by McQuay and colleagues. They also suggest that the new antidepressants and anticonvulsants give better analgesia with fewer side effects than the older drugs. For example, the new anticonvulsant gabapentin provided significant pain relief in placebo-controlled studies in patients with post-herpetic neuralgia and painful diabetic neuropathy.
NSAIDs
As part of their studies, McQuay's group also reviewed the literature on non-steroidal anti-inflammatory drugs (NSAIDs). They found that ibuprofen is the safest NSAID, no NSAID is more effective than another, and NSAIDs have a low incidence of potentially fatal problems. McQuay also refutes the argument that NSAIDs have a ceiling effect; he found greater efficacy at higher doses. Many experts, however, would argue this point.
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